← Leaderboards
Marta Wosinska
University Of California Berkeley
$2,372,015
Attributed
$2,372,015
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2018–21$2M$1.5M$1M$500K$0
'18
'19
'20
'21
Funding mix
By agency
FDA$2,372,015 · 3
AHRQ$0 · 1
By mechanism
U01$948,806 · 1
U19$823,209 · 1
U13$600,000 · 1
R03$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Berkeley
Same institution · by research overlap
- Albert Icksang Ko$18,319,672
- Purnima Madhivanan$5,784,882
- Eva Harris$40,012,308
- Ronald D Lee$15,560,657
- Jonathan D Wallis$16,826,005
Others in their field
Top investigators on “Choice”
- Greg Ulses · Consortium For Ocean Leadership, Inc$140,113,248
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$140,113,248
- David M Nathan · Massachusetts Institute Of Technology$119,550,018
- John M Lachin · George Washington University$118,921,924
- Jacqueline Moline · Icahn School Of Medicine At Mount Sinai$75,762,106
- Stephen Riordan · Westat, Inc.$67,484,510
Research focus
ChoiceClinical ResearchDrug /AgentHealth EconomicsHealth Science Research Analysis /EvaluationHuman DataTelecommunications
Grant awards (6)
Convener and organizer of activities and engagements focused on the development of medical products and related processes, surveillance, and policies relevant to ongoing public health activities$248,806
U01 · FY2021 · FD · contact PI
Convener and organizer of activities and engagements focused on the development of medical products and related processes, surveillance, and policies relevant to ongoing public health activities$250,000
U01 · FY2020 · FD · contact PI
Cooperative Agreement to Support Regulatory Research Related to the 2018 Prescription Drug User Fee Act and the 21st Century Cures Act (U19)$823,209
U19 · FY2019 · FD · contact PI
Convener and organizer of activities and engagements focused on the development of medical products and related processes, surveillance, and policies relevant to ongoing public health activities$450,000
U01 · FY2019 · FD · contact PI
Convener of Discussions on Medical Policy Issues Impacting Drug Development$600,000
U13 · FY2018 · FD · contact PI
Effects of Drug Advertising on Prescription Choice$0
R03 · FY2001 · HS